First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors - ScienceDirect

SciELO - Brasil - Fatty acid synthase as a potential new

Lipids and cancer: Emerging roles in pathogenesis, diagnosis and

FASN inhibitor TVB-3166 prevents S-acylation of the spike protein

FASN inhibitor TVB-3166 prevents S-acylation of the spike protein

Emerging roles of fatty acid metabolism in cancer and their

The role of lipids in cancer progression and metastasis

Frontiers First-In-Human Study to Assess the Safety

First-in-human study of the safety, pharmacokinetics, and

PDF) Metabolic dysregulation and emerging therapeutical targets

Suppressing fatty acid synthase by type I interferon and chemical

FASN inhibitor TVB-3166 prevents S-acylation of the spike protein

First-in-human study of the safety, pharmacokinetics, and